Who
Laura Brege
Director
Company insider
Files Form 4 as: Director, Mirum Pharmaceuticals; Director, Pacira BioSciences; Director, Edgewise Therapeutics; Director, ACADIA Pharmaceuticals; Director, Portola Pharmaceuticals; Director, Dynavax Technologies; Director, Aratana Therapeutics; Director, Delcath Systems.
In numbers
- Trades disclosed
- 279
- Buys
- 2
- Sells
- 40
- Bought
- $125K
- Sold
- $17.6M
- Companies
- 10
- Companies where not an officer
- 9
- First trade
- 12 Jun 2006
- Last trade
- 15 Jun 2026
- Last filed
- 17 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 15 Jun 2026filed 17 Jun 2026 | MIRM Mirum Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,772 at $0.00 | filing |
| 15 Jun 2026filed 17 Jun 2026 | MIRM Mirum Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,980 at $0.00 | filing |
| 15 Jun 2026filed 17 Jun 2026 | MIRM Mirum Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,772 at $0.00 | filing |
| 15 Jun 2026filed 17 Jun 2026 | MIRM Mirum Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,980 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | PCRX Pacira BioSciencesPharmaceuticals | SEC FORM 4 Code A | —6,405 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | PCRX Pacira BioSciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —10,891 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | PCRX Pacira BioSciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —10,891 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | PCRX Pacira BioSciencesPharmaceuticals | SEC FORM 4 Code A | —6,405 at $0.00 | filing |
| 5 Jun 2026filed 17 Jun 2026 | EWTX Edgewise Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,377 at $0.00 | filing |
| 5 Jun 2026filed 17 Jun 2026 | EWTX Edgewise Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,377 at $0.00 | filing |
| 29 May 2026filed 1 Jun 2026 | ACAD ACADIA PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | —8,107 | filing |
| 29 May 2026filed 1 Jun 2026 | ACAD ACADIA Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —8,107 at $0.00 | filing |
| 29 May 2026filed 1 Jun 2026 | ACAD ACADIA Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —16,004 at $0.00 | filing |
| 29 May 2026filed 1 Jun 2026 | ACAD ACADIA Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —8,107 at $0.00 | filing |
| 29 May 2026filed 1 Jun 2026 | ACAD ACADIA Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —16,004 at $0.00 | filing |
| 29 May 2026filed 1 Jun 2026 | ACAD ACADIA Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —9,311 at $0.00 | filing |
| 29 May 2026filed 1 Jun 2026 | ACAD ACADIA Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —9,311 at $0.00 | filing |
| 29 May 2026filed 1 Jun 2026 | ACAD ACADIA PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | —8,107 | filing |
| 11 Sep 2025filed 12 Sep 2025 | MIRM Mirum Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —17,000 at $0.00 | filing |
| 11 Sep 2025filed 12 Sep 2025 | MIRM Mirum PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $255K17,000 at $15.00 | filing |
News
Head-To-Head Comparison: ACADIA Pharmaceuticals (NASDAQ:ACAD) versus C4 Therapeutics (NASDAQ:CCCC)ACAD · tickerreport.com · 19 Oct 2026Critical Review: ACADIA Pharmaceuticals (NASDAQ:ACAD) and C4 Therapeutics (NASDAQ:CCCC)ACAD · dailypolitical.com · 15 Oct 2026ACADIA Pharmaceuticals (NASDAQ:ACAD) Cut to "Neutral" at UBS GroupACAD · themarketsdaily.com · 13 Oct 2026Mirum Pharmaceuticals to report Livmarli trial results Monday (MIRM:NASDAQ)MIRM · seekingalpha.com · 12 Oct 2026Pacira BioSciences (NASDAQ:PCRX) Upgraded at JPMorgan Chase & Co.PCRX · themarketsdaily.com · 11 Oct 2026
0 headlines in the last 90 days name Laura Brege; 5 articles from the last 14 days about the 3 companies they traded most, at most three about any one of them.